La catena delle opzioni mostra i dati chiave delle opzioni azionarie di 4D Molecular Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per 4D Molecular Therapeutics..

4D Molecular Therapeutics (NASDAQ:FDMT) Azioni, Catena delle Opzioni

4D Molecular Therapeutics

4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics Inc

AG Mortgage Investment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITT#NYSE">MITT</a>) reported quarterly earnings of $0.17 per share which beat the analyst consensus estimate of $0.16 by 6.25 percent.

Earnings

Earnings Beats

News

MITT

AG Mortgage Investment Q3 2024 Adj EPS $0.17 Beats $0.16 Estimate

WIIM

NXPI

NXP Semiconductors shares are trading lower after the company issued soft guidance.

2024 Outlook
The company raised its 2024 outlook for organic revenue growth to reflect strong year-to-date performance. All other measures in the outlook were maintained.
The company's outlook for 2024 in the table below assumes constant currency rates and excludes the impact of any future acquisitions or dispositions that may occur during the remainder of the year. Thomson Reuters believes that this type of guidance provides useful insight into the anticipated performance of its businesses.
The company expects its fourth-quarter 2024 organic revenue growth to be approximately 5% and its adjusted EBITDA margin to be approximately 37%.
The company continues to operate in an uncertain macroeconomic environment, reflecting ongoing geopolitical risk, uneven economic growth and an evolving interest rate and inflationary backdrop. Any worsening of the global economic or business environment, among other factors, could impact the company's ability to achieve its outlook.
Reported Full-Year 2023 Results and Full-Year 2024 Outlook
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">Total Thomson Reuters</td>
<td colspan="1" rowspan="1">
FY 2023
Reported
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
2/8/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
5/2/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
8/1/2024
</td>
<td colspan="1" rowspan="1">
FY 2024
Outlook
11/5/2024
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Total Revenue Growth</td>
<td colspan="1" rowspan="1">3&nbsp;%</td>
<td colspan="1" rowspan="1">~ 6.5%</td>
<td colspan="1" rowspan="1">6.5% - 7.0%</td>
<td colspan="1" rowspan="1">~ 7.0%</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Organic Revenue Growth(1)</td>
<td colspan="1" rowspan="1">6&nbsp;%</td>
<td colspan="1" rowspan="1">~ 6%</td>
<td colspan="1" rowspan="1">6.0% - 6.5%</td>
<td colspan="1" rowspan="1">~ 6.5%</td>
<td colspan="1" rowspan="1">~7.0%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA Margin(1)</td>
<td colspan="1" rowspan="1">39.3&nbsp;%</td>
<td colspan="1" rowspan="1">~ 38%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Corporate Costs</td>
<td colspan="1" rowspan="1">$115 million</td>
<td colspan="1" rowspan="1">$120 - $130 million</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow(1)</td>
<td colspan="1" rowspan="1">$1.9 billion</td>
<td colspan="1" rowspan="1">~ $1.8 billion</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Accrued Capex as % of Revenues(1)</td>
<td colspan="1" rowspan="1">7.8&nbsp;%</td>
<td colspan="1" rowspan="1">~ 8.5%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">
Depreciation &amp; Amortization of Computer Software
&nbsp;&nbsp;&nbsp; Depreciation &amp; Amortization of Internally
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Developed Software
&nbsp;&nbsp;&nbsp; Amortization of Acquired Software
</td>
<td colspan="1" rowspan="1">
$628 million
 $556 million
$72 million
</td>
<td colspan="1" rowspan="1">
$730 - $750 million
 $595 - $615 million
~ $135 million
</td>
<td colspan="1" rowspan="1">
Unchanged
 Unchanged
Unchanged
</td>
<td colspan="1" rowspan="1">
Unchanged
 $580 - $600 million
~ $150 million
</td>
<td colspan="1" rowspan="1">
Unchanged
 Unchanged
Unchanged
</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Interest Expense (P&amp;L)(2)</td>
<td colspan="1" rowspan="1">$164 million(2)</td>
<td colspan="1" rowspan="1">$150 - $170 million</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">$125 - $145&nbsp; million</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Effective Tax Rate on Adjusted Earnings(1)</td>
<td colspan="1" rowspan="1">16.5&nbsp;%</td>
<td colspan="1" rowspan="1">~ 18%</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
<td colspan="1" rowspan="1">Unchanged</td>
</tr>
</tbody>
</table>
</figure>

Guidance

Thomson Reuters Affirms FY24 Sales Guidance Of $7.27B Vs. $7.28B Estimate

Enpro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) reported quarterly earnings of $1.74 per share which missed the analyst consensus estimate of $1.87 by 6.95 percent. The company reported quarterly sales of $260.900 million which missed the analyst consensus estimate of $264.467 million by 1.35 percent. This is a 4.07 percent increase over sales of $250.700 million the same period last year.

Earnings Misses

Enpro Q3 2024 Adj. EPS $1.74 Misses $1.87 Estimate, Sales $260.900M Miss $264.467M Estimate

PLTR

Palantir shares are trading higher after the company reported better-than-expected Q3 financial results and issued guidance above consensus estimates.

MNDO

MIND C.T.I. Q3 EPS $0.04 Down From $0.06 YoY, Sales $5.21M Down From $5.26M YoY

Truist Securities analyst Jamie Cook upgrades MasTec (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) from Hold to Buy and raises the price target from $133 to $173.

Upgrades

Price Target

Analyst Ratings

Truist Securities Upgrades MasTec to Buy, Raises Price Target to $173

Enpro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPO#NYSE">NPO</a>) lowers FY2024 Adj EPS guidance from $7.00-7.60 to $6.75-7.00 vs $7.27 analyst estimate..

Enpro Lowers FY2024 Adj EPS Guidance from $7.00-7.60 to $6.75-7.00 vs $7.27 Est

Westlake Chemical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLKP#NYSE">WLKP</a>) reported quarterly earnings of $0.51 per share which beat the analyst consensus estimate of $0.36 by 41.67 percent. The company reported quarterly sales of $276.995 million which beat the analyst consensus estimate of $244.000 million by 13.52 percent. This is a 13.89 percent decrease over sales of $321.664 million the same period last year.

WLKP

Westlake Chemical Q3 2024 GAAP EPS $0.51 Beats $0.36 Estimate, Sales $276.995M Beat $244.000M Estimate

Sophia Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOPH#NASDAQ">SOPH</a>) affirms FY2024 sales outlook from $65.00 million-67.00 million to $65.00 million-67.00 million.

SOPH

Sophia Genetics Affirms FY2024 Sales Guidance to $65.00M-67.00M  VS Est. 65.66M

Biotech

Health Care

General

BEAM

Beam Therapeutics Ended Third Quarter 2024 With $925.8M In Cash, Cash Equivalents and Marketable Securities; Expected Operating Runway into 2027

Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) reported quarterly earnings of $1.48 per share which beat the analyst consensus estimate of $1.47 by 0.68 percent. This is a 14.73 percent increase over earnings of $1.29 per share from the same period last year. The company reported quarterly sales of $4.619 billion which beat the analyst consensus estimate of $4.566 billion by 1.16 percent. This is a 12.93 percent increase over sales of $4.090 billion the same period last year.

Emerson Electric Q4 2024 Adj. EPS $1.48 Beats $1.47 Estimate, Sales $4.619B Beat $4.566B Estimate

Westlake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) reported quarterly earnings of $1.41 per share which missed the analyst consensus estimate of $2.21 by 36.2 percent. The company reported quarterly sales of $3.117 billion which missed the analyst consensus estimate of $3.305 billion by 5.69 percent. This is a 0.06 percent increase over sales of $3.115 billion the same period last year.

Westlake Q3 2024 Adj. EPS $1.41 Misses $2.21 Estimate, Sales $3.117B Miss $3.305B Estimate

Hyster Yale (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HY#NYSE">HY</a>) reported quarterly earnings of $0.97 per share which missed the analyst consensus estimate of $1.97 by 50.76 percent. This is a 52.91 percent decrease over earnings of $2.06 per share from the same period last year. The company reported quarterly sales of $1.02 billion which missed the analyst consensus estimate of $1.06 billion by 3.82 percent. This is a 1.50 percent increase over sales of $1.00 billion the same period last year.

Hyster Yale Q3 2024 GAAP EPS $0.97 Misses $1.97 Estimate, Sales $1.02B Miss $1.06B Estimate

Beam Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAM#NASDAQ">BEAM</a>) reported quarterly losses of $(1.77) per share which missed the analyst consensus estimate of $(1.19) by 48.74 percent. This is a 45.08 percent decrease over losses of $(1.22) per share from the same period last year. The company reported quarterly sales of $14.27 million which missed the analyst consensus estimate of $14.50 million by 1.58 percent. This is a 17.01 percent decrease over sales of $17.19 million the same period last year.

Beam Therapeutics Q3 2024 GAAP EPS $(1.77) Misses $(1.19) Estimate, Sales $14.27M Miss $14.50M Estimate

Thomson Reuters (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TRI#NYSE">TRI</a>) reported quarterly earnings of $0.80 per share which beat the analyst consensus estimate of $0.77 by 3.9 percent. This is a 2.44 percent decrease over earnings of $0.82 per share from the same period last year. The company reported quarterly sales of $1.720 billion which beat the analyst consensus estimate of $1.713 billion by 0.39 percent. This is a 7.90 percent increase over sales of $1.594 billion the same period last year.

Thomson Reuters Q3 2024 Adj. EPS $0.80 Beats $0.77 Estimate, Sales $1.720B Beat $1.713B Estimate

Restaurant Brands International shares are trading lower following worse-than-expected Q3 financial results.

PINC

Premier Q1 2025 Adj. EPS $0.34 Beats $0.25 Estimate, Sales $248.142M Beat $232.843M Estimate

Restaurant Brands Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QSR#NYSE">QSR</a>) reported quarterly earnings of $0.93 per share which missed the analyst consensus estimate of $0.95 by 2.11 percent. The company reported quarterly sales of $2.291 billion which missed the analyst consensus estimate of $2.307 billion by 0.69 percent. This is a 24.71 percent increase over sales of $1.837 billion the same period last year.

Restaurant Brands Intl Q3 2024 Adj. EPS $0.93 Misses $0.95 Estimate, Sales $2.291B Miss $2.307B Estimate

Edward Jones analyst David Heger downgrades BCE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCE#NYSE">BCE</a>) from Buy to Hold.

Downgrades

Edward Jones Downgrades BCE to Hold

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on 4D Molecular Therapeutics (FDMT – Research Report) a...

Analysts Are Bullish on Top Healthcare Stocks: 4D Molecular Therapeutics (FDMT), Satellos Bioscience (MSCLF)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on 4D Molecular Therapeutics (FDMT – Research Report) and Progyny (P...

Analysts Have Conflicting Sentiments on These Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Progyny (PGNY)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on IGM Biosciences (IGMS – Research Report) and 4D Mole...

Analysts Are Bullish on These Healthcare Stocks: IGM Biosciences (IGMS), 4D Molecular Therapeutics (FDMT)

Janus Henderson Global Life Sciences Fund Q2 2024 Commentary

Janus Henderson Global Life Sciences Diversified ADR Managed Account Q2 2024 Commentary

4D Molecular Therapeutics downgraded at Cantor following wet AMD asset data

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Warning: FDMT is at high risk of performing badly

ABBV

ADVM

AMGN

ASND

AVDL

AZNCF

BHVN

ETNB

FDMT

GMED

IGMS

INSM

MSCLF

NONOF

NVSEF

PGNY

REGN

RGNX

SNYNF

SRPT

UTHR

VRTX

Press Releases

4DMT to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc. - FDMT

4DMT to Host 4D-150 Wet AMD Development Day on September 18, 2024

4DMT to Participate in the 2024 Cantor Global Healthcare Conference

4DMT Announces Presentations at Upcoming Retina Conferences

Small Cap

FDMT Investors Have Opportunity to Join 4D Molecular Therapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm

4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference

Comments

4D Molecular Therapeutics

4D Molecular Therapeutics (FDMT) Opzioni

4D Molecular Therapeutics (NASDAQ:FDMT) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO